Brief: Galapagos Initiates Late Stage Study With Filgotinib In Patients With Active Axial Spondyloarthritis
02/05/2023 23:32
May 2 (Reuters) - Galapagos NV GLPG.AS :
* GALAPAGOS INITIATES PHASE 3 PROGRAM WITH FILGOTINIB IN
PATIENTS
WITH ACTIVE AXIAL SPONDYLOARTHRITIS
Further company coverage: GLPG.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline